Tenax presents LEVEL topline results; primary endpoint neutral
Tenax reported topline and comprehensive LEVEL results, including about a 49% NT-proBNP reduction and a 3.5 mmHg decline in RVSP, while the trial missed its primary 6MWD endpoint.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.